References
Bassetti M, Righi E, De Pascale G, De Gaudio R, Giarratano A, Mazzei T, Morace G, Petrosillo N, Stefani S, Antonelli M (2014) How to manage aspergillosis in non-neutropenic intensive care unit patients. Crit Care 18(4):458. https://doi.org/10.1186/s13054-014-0458-4
Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE (2016) Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63(4):e1–e60. https://doi.org/10.1093/cid/ciw326
Theuretzbacher U, Ihle F, Derendorf H (2006) Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 45(7):649–663. https://doi.org/10.2165/00003088-200645070-00002
Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, Marchetti O (2012) Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 55(3):381–390. https://doi.org/10.1093/cid/cis437
Ibrahim RB, Liu C, Cronin SM, Murphy BC, Cha R, Swerdlow P, Edwards DJ (2007) Drug removal by plasmapheresis: an evidence-based review. Pharmacotherapy 27(11):1529–1549. https://doi.org/10.1592/phco.27.11.1529
Kintzel PE, Eastlund T, Calis KA (2003) Extracorporeal removal of antimicrobials during plasmapheresis. J Clin Apher 18(4):194–205. https://doi.org/10.1002/jca.10074
Spriet I, Bruggemann RJ, Annaert P, Meersseman P, Van Wijngaerden E, Lagrou K, Willems L (2013) Pharmacokinetic profile of voriconazole in a critically ill patient on therapeutic plasma exchange. Ther Drug Monit 35(1):141–143. https://doi.org/10.1097/FTD.0b013e31827d76b0
Pfizer Vfend: Summary of product characteristics. state of information: January 2017 https://www.fachinfo.de/pdf/015292 (accessed 08/2018)
Vanstraelen K, Wauters J, De Loor H, Vercammen I, Annaert P, Lagrou K, Spriet I (2014) Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis. J Pharm Sci 103(8):2565–2570. https://doi.org/10.1002/jps.24064
Preston C Stockley’s drug interactions [online]. In: ed Pharmaceutical Press www.medicinescomplete.com (accessed 08/2018)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent of the patient
Informed consent of the patient was obtained.
Rights and permissions
About this article
Cite this article
Vay, M., Foerster, K.I., Mahmoudi, M. et al. No alteration of voriconazole concentration by plasmapheresis in a critically ill patient. Eur J Clin Pharmacol 75, 287–288 (2019). https://doi.org/10.1007/s00228-018-2582-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-018-2582-6